HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure.

Abstract
Alterations in the ubiquitin-proteasome system (UPS) have been described in left ventricular hypertrophy and failure, although results have been inconsistent. The role of the UPS in right ventricular (RV) hypertrophy (RVH) and RV failure (RVF) is unknown. Given the greater percent increase in RV mass associated with RV afterload stress, as present in many congenital heart lesions, we hypothesized that alterations in the UPS could play an important role in RVH/RVF. UPS expression and activity were measured in the RV from mice with RVH/RVF secondary to pulmonary artery constriction (PAC). Epoxomicin and MG132 were used to inhibit the proteasome, and overexpression of the 11S PA28α subunit was used to activate the proteasome. PAC mice developed RVH (109.3% increase in RV weight to body weight), RV dilation with septal shift, RV dysfunction, and clinical RVF. Proteasomal function (26S β₅ chymotrypsin-like activity) was decreased 26% (P < 0.05). Protein expression of 19S subunit Rpt5 (P < 0.05), UCHL1 deubiquitinase (P < 0.0001), and Smurf1 E3 ubiquitin ligase (P < 0.01) were increased, as were polyubiquitinated proteins (P < 0.05) and free-ubiquitins (P = 0.05). Pro-apoptotic Bax was increased (P < 0.0001), whereas anti-apoptotic Bcl-2 decreased (P < 0.05), resulting in a sixfold increase in the Bax/Bcl-2 ratio. Proteasomal inhibition did not accelerate RVF. However, proteasome enhancement by cardiac-specific proteasome overexpression partially improved survival. Proteasome activity is decreased in RVH/RVF, associated with upregulation of key UPS regulators and pro-apoptotic signaling. Enhancement of proteasome function partially attenuates RVF, suggesting that UPS dysfunction contributes to RVF.
AuthorsViswanathan Rajagopalan, Mingming Zhao, Sushma Reddy, Giovanni Fajardo, Xuejun Wang, Shannamar Dewey, Aldrin V Gomes, Daniel Bernstein
JournalAmerican journal of physiology. Heart and circulatory physiology (Am J Physiol Heart Circ Physiol) Vol. 305 Issue 4 Pg. H551-62 (Aug 15 2013) ISSN: 1522-1539 [Electronic] United States
PMID23729213 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Proteasome Inhibitors
  • Ubiquitin
  • Proteasome Endopeptidase Complex
Topics
  • Animals
  • Apoptosis (drug effects)
  • Constriction
  • Disease Models, Animal
  • Gene Expression Regulation
  • Genetic Therapy
  • Heart Failure (enzymology, etiology, genetics, pathology, physiopathology, prevention & control)
  • Hemodynamics (drug effects)
  • Hypertrophy, Right Ventricular (enzymology, etiology, genetics, pathology, physiopathology, prevention & control)
  • Male
  • Mice
  • Mice, Transgenic
  • Myocardium (enzymology)
  • Proteasome Endopeptidase Complex (genetics, metabolism)
  • Proteasome Inhibitors (pharmacology)
  • Pulmonary Artery (physiopathology, surgery)
  • Signal Transduction (drug effects)
  • Time Factors
  • Ubiquitin (metabolism)
  • Ventricular Dysfunction, Right (enzymology, etiology, genetics, pathology, physiopathology, prevention & control)
  • Ventricular Function, Right (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: